
Renal Cell Carcinoma
Latest News
Advertisement
Latest Videos

Advertisement
More News










The treatment combination of the tyrosine kinase inhibitor axitinib plus pembrolizumab was tolerable in 52 patients with treatment-naïve advanced renal cell carcinoma, and the combination demonstrated promising antitumor activity, according to the lead researcher from Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Patients who have intermediate or poor-risk advanced renal cell carcinoma may see extended progression-free survival and overall survival in a phase II trial comparing pazopanib with temsirolimus, according to a presentation by Nizar M. Tannir, MD, FACP, at the 2018 Genitourinary Cancers Symposium.







Therapeutic Approach for Metastatic Renal Cell Carcinoma







Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
2
KLN-1010 In Vivo CAR Achieves 100% MRD Negativity in R/R Myeloma
3
FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer
4
FDA Grants Priority Review to Adjuvant Atezolizumab for dMMR Colon Cancer
5

















































